- Home
- HTBI vs ORIC Comparison
HTBI vs ORIC Comparison
Compare HTBI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- ORIC
- Stock Information
- Founded
- HTBI 1926
- ORIC 2014
- Country
- HTBI United States
- ORIC United States
- Employees
- HTBI N/A
- ORIC N/A
- Industry
- HTBI Savings Institutions
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- ORIC Health Care
- Exchange
- HTBI Nasdaq
- ORIC Nasdaq
- Market Cap
- HTBI 641.9M
- ORIC 633.7M
- IPO Year
- HTBI 2012
- ORIC 2020
- Fundamental
- Price
- HTBI $31.60
- ORIC $7.96
- Analyst Decision
- HTBI Buy
- ORIC Strong Buy
- Analyst Count
- HTBI 4
- ORIC 9
- Target Price
- HTBI $39.00
- ORIC $18.75
- AVG Volume (30 Days)
- HTBI 33.4K
- ORIC 483.1K
- Earning Date
- HTBI 01-22-2025
- ORIC 11-12-2024
- Dividend Yield
- HTBI 1.52%
- ORIC N/A
- EPS Growth
- HTBI 14.18
- ORIC N/A
- EPS
- HTBI 3.52
- ORIC N/A
- Revenue
- HTBI $187,440,000.00
- ORIC N/A
- Revenue This Year
- HTBI N/A
- ORIC N/A
- Revenue Next Year
- HTBI N/A
- ORIC N/A
- P/E Ratio
- HTBI $8.98
- ORIC N/A
- Revenue Growth
- HTBI 2.84
- ORIC N/A
- 52 Week Low
- HTBI $23.55
- ORIC $6.33
- 52 Week High
- HTBI $38.99
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- HTBI 28.44
- ORIC 42.38
- Support Level
- HTBI $32.80
- ORIC $8.16
- Resistance Level
- HTBI $33.74
- ORIC $9.47
- Average True Range (ATR)
- HTBI 0.83
- ORIC 0.51
- MACD
- HTBI -0.19
- ORIC 0.05
- Stochastic Oscillator
- HTBI 5.85
- ORIC 25.62
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.